Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12737365 | 1.00 | PTPN11 (0.39) | PTPN11CYP2C9MOGAT2FFAR4FFAR1 | |
| SCHEMBL12737364 | 1.00 | PTPN11 (0.39) | PTPN11CYP2C9MOGAT2FFAR4FFAR1 | |
| SCHEMBL12737363 | 0.99 | PTPN11 (0.38) | PTPN11CYP2C9MOGAT2FFAR4FFAR1 | |
| SCHEMBL12737361 | 0.97 | FFAR4 (0.39) | PTPN11CYP2C9MOGAT2FFAR4FFAR1 | |
| SCHEMBL12742439 | 0.93 | PTPN11 (0.39) | PTPN11CYP2C9MOGAT2PPARDCRBN | |
| SCHEMBL12742442 | 0.93 | PTPN11 (0.39) | PTPN11CYP2C9MOGAT2PPARDCRBN | |
| SCHEMBL12742447 | 0.93 | PTPN11 (0.39) | PTPN11CYP2C9MOGAT2PPARDCRBN | |
| SCHEMBL14766109 | 0.93 | FFAR4 (0.43) | PTPN11FFAR4FFAR1PPARDCRBN | |
| SCHEMBL12742432 | 0.92 | PTPN11 (0.38) | PTPN11CYP2C9MOGAT2FFAR1PPARD | |
| SCHEMBL14766206 | 0.91 | FFAR4 (0.42) | PTPN11FFAR4FFAR1PPARDCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | PTPN11 3889/4885CYP2C9 2816/4885MOGAT2 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.